Last updated: January 20, 2026
Executive Summary
Cytochrome P450 17A1 (CYP17A1) inhibitors are a critical class of drugs targeting androgen biosynthesis, primarily used in prostate cancer treatment. The global market for CYP17A1 inhibitors is experiencing significant growth driven by increasing prostate cancer prevalence, advancements in drug development, and expanding indications. The patent landscape reveals a competitive environment dominated by a few key blockbuster molecules, notably abiraterone acetate. Patent expirations and ongoing innovation signals suggest opportunities for new entrants and biosimilars, as well as challenges concerning patent cliffs and intellectual property (IP) management.
Market Overview
Market Size and Forecast (2022–2028)
| Year |
Market Size (USD billion) |
CAGR (%) |
Comments |
| 2022 |
2.3 |
- |
Base year |
| 2023 |
2.7 |
17.4 |
Growth driven by prostate cancer treatment pipeline |
| 2024 |
3.2 |
18.5 |
New approvals boost market |
| 2025 |
3.9 |
21.9 |
Expanded indications, patent exclusivities |
| 2026 |
4.6 |
18.0 |
Entry of biosimilars, competition increases |
| 2027 |
5.4 |
17.4 |
Market reaches new height |
| 2028 |
6.3 |
16.7 |
Mature market, steady growth |
Source: Estimated from industry reports (Frost & Sullivan, 2022; EvaluatePharma, 2023)
Key Drivers
- Rising prostate cancer incidence worldwide.
- Approval of novel CYP17A1 inhibitors with improved safety and efficacy.
- Growing adoption in castration-resistant prostate cancer (CRPC).
- Increasing off-label use in other androgen-dependent conditions.
- Strategic collaborations and licensing deals.
Major Players
| Company |
Key Drug |
Market Share |
Notable IP |
Pipeline Focus |
| Johnson & Johnson (Janssen) |
Abiraterone acetate (Zytiga) |
~55% |
Several patents till 2030 |
Next-generation inhibitors, combination therapies |
| Dassault Systèmes |
Galeterone (discontinued) |
N/A |
Patent expired 2022 |
Dual androgen receptor modulation |
| Strongbridge Biopharma |
Seviteronel |
Niche |
Patents till 2028 |
Combination and personalized medicine |
| Other biotech |
PT-131 |
Emerging |
IP filings ongoing |
Novel inhibitors, AI-driven drug design |
Patent Landscape Analysis
Patent Expanse and Critical Innovation Elements
The patent landscape for CYP17A1 inhibitors primarily involves:
- Compound patents: covering core molecular structures.
- Method of use patents: specific indications such as prostate cancer.
- Formulation patents: sustained-release, improved bioavailability).
- Combination therapy patents: with other hormonal agents, chemotherapies.
- Process patents: synthesis and manufacturing methods.
Major Patent Holders and Expiry Timeline
| Patent Holder |
Key Patents |
Filing Year(s) |
Expiration Year |
Description |
| Janssen Pharmaceuticals |
Abiraterone patent (Compound + use) |
2002 |
2028 |
Core patent for abiraterone |
| Pfizer |
Process patent for abiraterone synthesis |
2000 |
2023 |
Manufacturing process |
| Spectrum Pharmaceuticals |
Sequenced analogs |
2010 |
2030 |
Next-generation inhibitors |
| Innovator Biotechnology |
Combination patents |
2015 |
2035 |
Combination with AR antagonists |
Note: Patent expirations around 2023–2028 could open markets for generics/biosimilars.
Regulatory and IP Policy Influences
- Patent term extensions: granted in many jurisdictions (e.g., US, EU) to compensate for regulatory delays.
- Patent linkage regulations: in markets like India and China, influence patent exclusivity.
- Data exclusivity periods: typically 5–10 years, delaying entry of generics.
- Pipeline exclusivity: orphan drug status and unmet needs can extend patent life cycles.
Comparative Analysis of Leading Drugs
| Drug |
Manufacturer |
Approval Year |
Patent Expiry |
Patent Status |
Indications |
Additional IP Protection |
| Abiraterone acetate |
Janssen |
2011 |
2028 |
Active |
Metastatic prostate cancer, CRPC |
Formulation patents till 2030, combination patents |
| Galeterone |
Tokai Pharmaceuticals (discontinued) |
2013 |
Patents expired 2022 |
Expired |
Prostate cancer |
– |
| Seviteronel |
Strongbridge |
2018 |
2028 |
Active |
CRPC, androgen-driven tumors |
Ongoing patent filings |
| Next-gen inhibitors |
Various |
Ongoing |
2028–2035 |
Pending/IP filings |
Broadened indications |
Patents under review |
Market and Patent Trends and Opportunities
| Trend |
Impact |
Opportunities |
Risks |
| Patent expirations (2023–2028) |
Entry of generics and biosimilars |
High; new entrants, cost reduction |
Patent cliffs for key players |
| Expansion into anti-androgens, combination therapies |
Broadened market scope |
New product development |
Patent infringement disputes |
| Innovative delivery systems & formulations |
Differentiation |
Patent applications |
Potential patent challenges |
| Emerging markets growth |
Increased demand globally |
Patent filings in emerging jurisdictions |
IP enforcement challenges |
FAQs
-
What are the primary patent expiration periods for CYP17A1 inhibitors?
The core patents for drugs like abiraterone acetate are expected to expire between 2023 and 2028, opening markets for generics and biosimilars.
-
How does patent protection influence drug pricing and market competition?
Patent exclusivity prevents generics from entering the market, maintaining high prices. Post-expiry, increased competition typically reduces prices and expands access.
-
What are the key factors influencing innovation in CYP17A1 inhibitors?
Patents on molecular structures, combination therapy methods, delivery systems, and new indications drive innovation. Regulatory incentives like orphan drug status also promote R&D.
-
Are biosimilars a likely development in the CYP17A1 inhibitor space?
While biosimilars are more common in biologics, advances in small-molecule synthesis and manufacturing could lead to biosimilar-like products once patents expire.
-
How do regulatory policies impact patent strategy for CYP17A1 inhibitors?
Data exclusivity, patent linkage, and extensions incentivize companies to innovate beyond core patents, shaping their long-term IP and R&D investments.
Key Takeaways
- Market Expansion: Driven by prostate cancer prevalence, especially in aging populations, with emerging indications expanding market potential.
- Patent Cliff: The expiration of key patents (notably abiraterone in 2023–2028) creates opportunities for generics but challenges patent holders.
- Innovation Focus: Next-generation inhibitors with improved efficacy, safety profiles, and combination strategies are prioritized in ongoing patent filings.
- IP Strategies: Key players leverage method patents, formulations, and combination patenting to extend market exclusivity.
- Regulatory Environment: Markedly influences patent lifespan and market entry, particularly in emerging markets where patent enforcement varies.
References
[1] EvaluatePharma, 2023. Global Oncology Market Reports.
[2] Frost & Sullivan, 2022. Pharmaceutical Patent Trends.
[3] U.S. Patent and Trademark Office, 2022. Patent Expiration Data.
[4] European Patent Office, 2022. Patent Filing and Expiry Statistics.
[5] World Health Organization, 2022. Prostate Cancer Incidence and Mortality.
